ClinicalTrials.gg
CompletedNCT02912468SINUS-24Updated Jul 25, 2019Results posted

A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps

A Phase 3 interventional study of Dupilumab SAR231893 (REGN668) and Placebo in Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), sponsored by Sanofi. Completed at 76 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.

Enrollment
3rd of 16
276 · median 45
Started
2016
with 1 other
Phase 3
4 of 16
none open now
Registered
3rd of 16
by date
Lead sponsor
5 of 16
Sanofi

Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 3rd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing dupilumab in Nasal Polyps, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab 300 milligram (mg) every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyp score (NPS) in participants with bilateral nasal polyposis (NP). In addition for Japan participants, reduction in computed tomography (CT) scan opacification of the sinuses was a coprimary objective.

Secondary Objectives:

  • To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).
  • To evaluate the efficacy of dupilumab in improving sense of smell.
  • To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (primary objective for Japan).
  • To evaluate ability of dupilumab in reducing proportion of participants requiring treatment with systemic corticosteroids or NP surgery.
  • To evaluate the effect of dupilumab on participant reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).
  • To evaluate the effect of dupilumab in the subgroups of participants with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease [ERD]).
  • To evaluate residual effect in follow up.
  • To evaluate the safety of dupilumab in participants with bilateral NP.
  • To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatment-emergent anti-drug antibodies.
Read the detailed description

The total study duration per participant was expected to be up to 52 weeks that consisted of a 4-weeks run-in period, 24-weeks treatment period, and a 24-weeks post treatment period.

03

Conditions studied

  • Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Browse trials for

Keywords

  • Nasal polyposis, Chronic rhinosinusitis, Intranasal corticosteroids, Dupilumab, Human monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with bilateral sinonasal polyposis that despite prior treatment with systemic (SCS) anytime within the past 2 years; and/or had a medical / intolerance to SCS; and/or had prior surgery for NP at the screening visit, had:
  • An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).
  • Ongoing symptoms (for at least 8 weeks prior to Visit [V] 1) of nasal congestion/blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at the time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Participants \<18 years of age.
  • Participants who were previously treated in dupilumab studies.
  • Participants who had taken:
  • Biologic therapy/systemic to treat inflammatory disease or disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever was longer.
  • Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life was unknown.
  • Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days prior to V1.
  • Participants who received leukotriene antagonists/modifiers at V1 unless they were on a continuous treatment for at least 30 days prior to V1.
  • Initiated allergen immunotherapy within 3 months prior to V1 or planned to begin therapy or changed its dose during the run-in period or the randomized treatment period.
  • Participants who undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months prior to V1.
  • Participants who had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.
  • Participants with conditions/concomitant diseases making them nonevaluable at V1 or for the primary efficacy endpoint such as:
  • Antrochoanal polyps;
  • Nasal septal deviation that would occlude at least one nostril;
  • Acute sinusitis, nasal infection or upper respiratory infection;
  • Ongoing rhinitis medicamentosa;
  • Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis;
  • Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.
  • Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil, etc).
  • Participants with (FEV1) 50% or less (of predicted normal).
  • Participants who received concomitant treatment prohibited in the study.
  • Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
  • History of (HIV) infection or positive HIV serology at screening.
  • Positive with surface antigen (HBsAg) or antibody at the screening visit.
  • Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit.
  • Known or suspected history of immunosuppression.
  • Pregnant or breastfeeding women, or women planned to become pregnant or breastfeed during the study.
  • Women unwilling to use adequate , if of and sexually active.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
276 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.

    Drug: Placebo · Drug: Mometasone furoate 50 micrograms

  • Experimental
    Dupilumab 300 mg

    Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.

    Drug: Dupilumab SAR231893 (REGN668) · Drug: Mometasone furoate 50 micrograms

Interventions

  • Pharmaceutical form: Solution Route of administration: Subcutaneous

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: Subcutaneous

  • Pharmaceutical form: Suspension (Nasal spray) Route of administration: Intranasal

    Also known as: NASONEX®

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Least squares (LS) means and standard error (SE) were obtained from Analysis of covariance (ANCOVA) model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 24

  2. Change From Baseline at Week 24 in Nasal Polyp Score

    NPS: sum of right, left nostril scores, evaluated by nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller-sized polyps. Total NPS: sum of right and left nostril scores; ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund-Mackay (LMK) Score

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. NOTE: For Japan regulatory submission only, this endpoint is not included as a secondary outcome measure and is instead one of the co-primary outcome measures.

    Time frame: Baseline, Week 24

  2. Change From Baseline at Week 24 in Total Symptom Score (TSS)

    The TSS was the sum of participant-assessed nasal symptom scores for nasal congestion/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 24

  3. Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score

    The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 24

  4. Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily

    The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 24

  5. Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores

    The SNOT-22 is a validated questionnaire that was used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 24

  6. Rescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 24 Obtained Using Kaplan-Meier Method

    Rescue treatment was defined as usage of systemic corticosteroids (SCS) or NP surgery (actual or planned) during the treatment period. Rescue treatment included: * SCS: Betamethasone, dexamethasone, dexamethasone sodium phosphate, Hydrocortisone sodium succinate, methylprednisolone, prednisolone, prednisolone metasulfobenzoate sodium, prednisone, and triamcinolone. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 24 was obtained using Kaplan-Meier method.

    Time frame: Baseline up to Week 24

  7. Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis

    The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters (cm) VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 24

  8. Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)

    NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute. Higher NPIF values are indicative of better nasal air flow. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 24

  9. Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score

    Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 24

  10. Change From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 24

  11. Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) Scores for Participants With Asthma

    ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with the corresponding baseline value, treatment group, prior surgery, and regions as covariates.

    Time frame: Baseline, Week 24

  12. Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Nasal Congestion Symptom Severity Score (Assessments Performed 4-24 Weeks After End of Treatment)

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)

  13. Change From Baseline at Weeks 36 and 48 in Nasal Polyp Score (Assessments Performed 12 and 24 Weeks After End of Treatment)

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

    Time frame: Baseline, Week 36, Week 48 (post-baseline assessments performed 12 and 24 weeks after end of treatment)

  14. Change From Baseline at Week 48 in Opacification of Sinuses Measured by Lund-Mackay Score (Assessment Performed 24 Weeks After End of Treatment)

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)

  15. Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Total Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)

    The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)

  16. Change From Baseline at Week 48 in University of Pennsylvania Smell Identification Test (Assessment Performed 24 Weeks After End of Treatment)

    The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)

  17. Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily (Assessments Performed 4-24 Weeks After End of Treatment)

    The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)

  18. Change From Baseline at Weeks 36 and 48 in 22-item Sino-nasal Outcome Test Scores (Assessments Performed 12 and 24 Weeks After End of Treatment)

    The SNOT-22 is a validated questionnaire that was used to assess the impact of CRSwNP on HRQoL. It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 36 and Week 48 (Post-baseline assessments performed 12 and 24 weeks after end of treatment)

  19. Rescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 48 Obtained Using Kaplan-Meier Method

    Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the study. Rescue treatment included: * SCS: Betamethasone, dexamethasone, dexamethasone sodium phosphate, Hydrocortisone sodium succinate, methylprednisolone, prednisolone, prednisolone metasulfobenzoate sodium, prednisone, and triamcinolone. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 48 was obtained using Kaplan-Meier method.

    Time frame: Baseline up to Week 48

  20. Change From Baseline at Weeks 36 and 48 in Visual Analog Scale for Rhinosinusitis (Assessments Performed 12 and 24 Weeks After End of Treatment)

    The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 cm VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 36 and Week 48 (Post-baseline assessments performed 12 and 24 weeks after end of treatment)

  21. Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Rhinorrhea Daily Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)

    Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)

  22. Change From Baseline at Week 48 in Forced Expiratory Volume in 1 Second for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)

  23. Change From Baseline at Week 48 in Asthma Control Questionnaire-6 Scores for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)

    ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with the corresponding baseline value, treatment group, prior surgery, and regions as covariates.

    Time frame: Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)

  24. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation

    An Adverse Event (AE) was defined as any untoward medical occurrence that did not necessarily have to have a causal relationship with the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of study drug until 98 days following the last administration of study drug. Serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

    Time frame: Baseline up to 98 days following the last administration of study drug (up to 36 weeks)

  25. Functional Dupilumab Concentration in Serum

    Time frame: Baseline, Week 4, 8, 16, 24, 36, End of study (Week 48)

  26. Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response

    ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as a positive response in the ADA assay post first dose, when baseline results are negative or missing. 2) Treatment boosted was defined as: An ADA positive response in the assay post first dose that is greater-than or equal to 4-fold over baseline titer levels, when baseline results are positive.

    Time frame: Baseline to End of study (Week 48)

  27. Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period

    SCS included: Betamethasone, dexamethasone, dexamethasone sodium phosphate, hydrocortisone sodium succinate, methylprednisolone, prednisolone, prednisolone metasulfobenzoate sodium, prednisone, and triamcinolone. For every participant, total dose was calculated as (prescribed total daily dose\*duration of SCS use). Then, mean of the total dose of 25 participants (placebo group) and 9 participants (Dupilumab group) was derived.

    Time frame: Baseline to Week 24

  28. Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant

    Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the treatment period. SCS rescue intake duration was defined as the duration (in days) from start of SCS rescue medication till the end of SCS rescue treatment.

    Time frame: Baseline to Week 24

  29. Change From Baseline at Week 24 in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale Score

    The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ-VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

    Time frame: Baseline, Week 24

  30. Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Asthma

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 24

  31. Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

    Time frame: Baseline, Week 24

  32. Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

    Time frame: Baseline, Week 24

  33. Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

    Time frame: Baseline, Week 24

  34. Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 24

  35. Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

    Time frame: Baseline, Week 24

07

Results

Posted Jul 25, 2019

Participant flow

Participants were involved in the study from 05 December 2016 to 05 July 2018 at 67 active centers in 13 countries. A total of 506 participants were screened, of which 276 participants were enrolled and randomized to receive dupilumab 300 mg or placebo. A total of 230 participants failed screening mainly due to failure to meet inclusion criteria.

Participant flow — Overall Study
MilestonePlaceboDupilumab 300 mg
Started133143
Treated133142
Safety population132143
Completed124138
Not completed95
Withdrew: Adverse event32
Withdrew: Withdrawal by subject62
Withdrew: Randomized and not treated01

Outcome measures

PrimaryChange From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Least squares (LS) means and standard error (SE) were obtained from Analysis of covariance (ANCOVA) model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score-0.45 ± 0.07-1.34 ± 0.07
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <0.0001 · Ls mean difference: -0.89 · 95% CI -1.07 to -0.71
PrimaryChange From Baseline at Week 24 in Nasal Polyp Score

NPS: sum of right, left nostril scores, evaluated by nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller-sized polyps. Total NPS: sum of right and left nostril scores; ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Polyp Score
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Polyp Score0.17 ± 0.15-1.89 ± 0.14
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <0.0001 · Ls mean difference: -2.06 · 95% CI -2.43 to -1.69
SecondaryChange From Baseline at Week 24 in Opacification of Sinuses Measured by Lund-Mackay (LMK) Score

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. NOTE: For Japan regulatory submission only, this endpoint is not included as a secondary outcome measure and is instead one of the co-primary outcome measures.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund-Mackay (LMK) Score
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund-Mackay (LMK) Score-0.74 ± 0.37-8.18 ± 0.34
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -7.44 · 95% CI -8.35 to -6.53
SecondaryChange From Baseline at Week 24 in Total Symptom Score (TSS)

The TSS was the sum of participant-assessed nasal symptom scores for nasal congestion/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Total Symptom Score (TSS)
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Total Symptom Score (TSS)-1.17 ± 0.17-3.77 ± 0.16
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -2.61 · 95% CI -3.04 to -2.17
SecondaryChange From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score

The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score0.70 ± 0.7111.26 ± 0.67
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 10.56 · 95% CI 8.79 to 12.34
SecondaryChange From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily

The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily-0.29 ± 0.07-1.41 ± 0.07
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -1.12 · 95% CI -1.31 to -0.93
SecondaryChange From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores

The SNOT-22 is a validated questionnaire that was used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores-9.31 ± 1.62-30.43 ± 1.54
Statistical analysis
  • Placebo vs Dupilumab 300 mg · ANCOVA · p = <.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -21.12 · 95% CI -25.17 to -17.06
SecondaryRescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 24 Obtained Using Kaplan-Meier Method

Rescue treatment was defined as usage of systemic corticosteroids (SCS) or NP surgery (actual or planned) during the treatment period. Rescue treatment included: * SCS: Betamethasone, dexamethasone, dexamethasone sodium phosphate, Hydrocortisone sodium succinate, methylprednisolone, prednisolone, prednisolone metasulfobenzoate sodium, prednisone, and triamcinolone. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 24 was obtained using Kaplan-Meier method.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants with event
Rescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 24 Obtained Using Kaplan-Meier Method
percentage of participants with eventPlaceboDupilumab 300 mg
SCS treatment18.9 (12.7 to 26.0)6.5 (3.2 to 11.5)
NP surgery7.5 (3.7 to 13.2)2.1 (0.6 to 5.6)
SecondaryChange From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis

The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters (cm) VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · centimeters
Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis
centimetersPlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis-1.34 ± 0.24-4.54 ± 0.23
SecondaryChange From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)

NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute. Higher NPIF values are indicative of better nasal air flow. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · liters per minute
Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)
liters per minutePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)14.09 ± 3.9754.50 ± 3.73
SecondaryChange From Baseline at Week 24 in Rhinorrhea Daily Symptom Score

Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score-0.42 ± 0.06-1.04 ± 0.06
SecondaryChange From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · liters
Change From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma
litersPlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma-0.06 ± 0.050.15 ± 0.05
SecondaryChange From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) Scores for Participants With Asthma

ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with the corresponding baseline value, treatment group, prior surgery, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) Scores for Participants With Asthma
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) Scores for Participants With Asthma-0.24 ± 0.10-1.00 ± 0.10
SecondaryChange From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Nasal Congestion Symptom Severity Score (Assessments Performed 4-24 Weeks After End of Treatment)

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Nasal Congestion Symptom Severity Score (Assessments Performed 4-24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Week 28-0.48 ± 0.07-1.36 ± 0.07
Week 32-0.50 ± 0.07-1.33 ± 0.07
Week 36-0.53 ± 0.07-1.05 ± 0.07
Week 40-0.51 ± 0.08-0.83 ± 0.07
Week 44-0.49 ± 0.08-0.77 ± 0.07
Week 48-0.52 ± 0.08-0.77 ± 0.07
SecondaryChange From Baseline at Weeks 36 and 48 in Nasal Polyp Score (Assessments Performed 12 and 24 Weeks After End of Treatment)

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

Time frame:
Baseline, Week 36, Week 48 (post-baseline assessments performed 12 and 24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Weeks 36 and 48 in Nasal Polyp Score (Assessments Performed 12 and 24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Week 36-0.06 ± 0.14-0.99 ± 0.13
Week 480.14 ± 0.13-0.66 ± 0.12
SecondaryChange From Baseline at Week 48 in Opacification of Sinuses Measured by Lund-Mackay Score (Assessment Performed 24 Weeks After End of Treatment)

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 48 in Opacification of Sinuses Measured by Lund-Mackay Score (Assessment Performed 24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 48 in Opacification of Sinuses Measured by Lund-Mackay Score (Assessment Performed 24 Weeks After End of Treatment)-0.82 ± 0.38-2.62 ± 0.36
SecondaryChange From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Total Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)

The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Total Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Week 28-1.18 ± 0.17-3.84 ± 0.16
Week 32-1.25 ± 0.17-3.64 ± 0.17
Week 36-1.31 ± 0.18-2.91 ± 0.17
Week 40-1.27 ± 0.18-2.28 ± 0.17
Week 44-1.20 ± 0.18-2.09 ± 0.17
Week 48-1.28 ± 0.19-2.05 ± 0.18
SecondaryChange From Baseline at Week 48 in University of Pennsylvania Smell Identification Test (Assessment Performed 24 Weeks After End of Treatment)

The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 48 in University of Pennsylvania Smell Identification Test (Assessment Performed 24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 48 in University of Pennsylvania Smell Identification Test (Assessment Performed 24 Weeks After End of Treatment)0.21 ± 0.774.20 ± 0.73
SecondaryChange From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily (Assessments Performed 4-24 Weeks After End of Treatment)

The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily (Assessments Performed 4-24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Week 28-0.28 ± 0.08-1.45 ± 0.07
Week 32-0.31 ± 0.08-1.36 ± 0.07
Week 36-0.33 ± 0.08-1.07 ± 0.07
Week 40-0.30 ± 0.07-0.83 ± 0.07
Week 44-0.28 ± 0.07-0.74 ± 0.07
Week 48-0.30 ± 0.07-0.71 ± 0.06
SecondaryChange From Baseline at Weeks 36 and 48 in 22-item Sino-nasal Outcome Test Scores (Assessments Performed 12 and 24 Weeks After End of Treatment)

The SNOT-22 is a validated questionnaire that was used to assess the impact of CRSwNP on HRQoL. It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 36 and Week 48 (Post-baseline assessments performed 12 and 24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Weeks 36 and 48 in 22-item Sino-nasal Outcome Test Scores (Assessments Performed 12 and 24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Week 36-8.31 ± 1.75-20.87 ± 1.67
Week 48-8.36 ± 1.88-17.66 ± 1.80
SecondaryRescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 48 Obtained Using Kaplan-Meier Method

Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the study. Rescue treatment included: * SCS: Betamethasone, dexamethasone, dexamethasone sodium phosphate, Hydrocortisone sodium succinate, methylprednisolone, prednisolone, prednisolone metasulfobenzoate sodium, prednisone, and triamcinolone. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 48 was obtained using Kaplan-Meier method.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants with event
Rescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 48 Obtained Using Kaplan-Meier Method
percentage of participants with eventPlaceboDupilumab 300 mg
SCS treatment28.8 (21.4 to 36.7)21.4 (15.0 to 28.5)
NP surgery12.5 (7.5 to 18.9)6.3 (2.9 to 11.4)
SecondaryChange From Baseline at Weeks 36 and 48 in Visual Analog Scale for Rhinosinusitis (Assessments Performed 12 and 24 Weeks After End of Treatment)

The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 cm VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 36 and Week 48 (Post-baseline assessments performed 12 and 24 weeks after end of treatment)
Reported as:
Least squares mean · centimeters
Change From Baseline at Weeks 36 and 48 in Visual Analog Scale for Rhinosinusitis (Assessments Performed 12 and 24 Weeks After End of Treatment)
centimetersPlaceboDupilumab 300 mg
Week 36-1.36 ± 0.26-3.02 ± 0.25
Week 48-1.17 ± 0.25-2.42 ± 0.24
SecondaryChange From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Rhinorrhea Daily Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)

Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48 (Post-baseline assessments performed 4-24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Rhinorrhea Daily Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Week 28-0.42 ± 0.06-1.04 ± 0.06
Week 32-0.43 ± 0.06-0.97 ± 0.06
Week 36-0.44 ± 0.07-0.80 ± 0.06
Week 40-0.44 ± 0.07-0.63 ± 0.06
Week 44-0.41 ± 0.07-0.58 ± 0.06
Week 48-0.45 ± 0.07-0.58 ± 0.07
SecondaryChange From Baseline at Week 48 in Forced Expiratory Volume in 1 Second for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)
Reported as:
Least squares mean · liters
Change From Baseline at Week 48 in Forced Expiratory Volume in 1 Second for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)
litersPlaceboDupilumab 300 mg
Change From Baseline at Week 48 in Forced Expiratory Volume in 1 Second for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)-0.11 ± 0.05-0.05 ± 0.05
SecondaryChange From Baseline at Week 48 in Asthma Control Questionnaire-6 Scores for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)

ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with the corresponding baseline value, treatment group, prior surgery, and regions as covariates.

Time frame:
Baseline, Week 48 (Post-baseline assessment performed 24 weeks after end of treatment)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 48 in Asthma Control Questionnaire-6 Scores for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 48 in Asthma Control Questionnaire-6 Scores for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)-0.09 ± 0.11-0.55 ± 0.11
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation

An Adverse Event (AE) was defined as any untoward medical occurrence that did not necessarily have to have a causal relationship with the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of study drug until 98 days following the last administration of study drug. Serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

Time frame:
Baseline up to 98 days following the last administration of study drug (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation
ParticipantsPlaceboDupilumab 300 mg
Any TEAE9393
Any treatment emergent SAE196
TEAE leading to treatment discontinuation35
SecondaryFunctional Dupilumab Concentration in Serum
Time frame:
Baseline, Week 4, 8, 16, 24, 36, End of study (Week 48)
Reported as:
Mean · nanogram/milliliter
Functional Dupilumab Concentration in Serum
nanogram/milliliterDupilumab 300 mg
Baseline0.00 ± 0.00
Week 431267.18 ± 13008.16
Week 848306.73 ± 20621.18
Week 1663958.12 ± 29822.30
Week 2469224.11 ± 36933.70
Week 36356.53 ± 1501.69
Week 4839.00 ± 0.00
SecondaryNumber of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response

ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as a positive response in the ADA assay post first dose, when baseline results are negative or missing. 2) Treatment boosted was defined as: An ADA positive response in the assay post first dose that is greater-than or equal to 4-fold over baseline titer levels, when baseline results are positive.

Time frame:
Baseline to End of study (Week 48)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response
ParticipantsPlaceboDupilumab 300 mg
With treatment-emergent ADA722
With treatment-boosted ADA00
SecondaryMean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period

SCS included: Betamethasone, dexamethasone, dexamethasone sodium phosphate, hydrocortisone sodium succinate, methylprednisolone, prednisolone, prednisolone metasulfobenzoate sodium, prednisone, and triamcinolone. For every participant, total dose was calculated as (prescribed total daily dose\*duration of SCS use). Then, mean of the total dose of 25 participants (placebo group) and 9 participants (Dupilumab group) was derived.

Time frame:
Baseline to Week 24
Reported as:
Mean · milligrams
Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period
milligramsPlaceboDupilumab 300 mg
Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period366.07 ± 247.07686.65 ± 1575.86
SecondaryTotal Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant

Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the treatment period. SCS rescue intake duration was defined as the duration (in days) from start of SCS rescue medication till the end of SCS rescue treatment.

Time frame:
Baseline to Week 24
Reported as:
Mean · days
Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant
daysPlaceboDupilumab 300 mg
Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant11.04 ± 6.7923.33 ± 50.13
SecondaryChange From Baseline at Week 24 in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale Score

The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ-VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale Score
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale Score1.74 ± 1.5412.00 ± 1.48
SecondaryChange From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Asthma

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Asthma-0.36 ± 0.09-1.48 ± 0.09
SecondaryChange From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery-0.52 ± 0.09-1.41 ± 0.08
SecondaryChange From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma0.27 ± 0.20-1.89 ± 0.20
SecondaryChange From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery0.14 ± 0.18-1.86 ± 0.18
SecondaryChange From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma-0.15 ± 0.47-7.97 ± 0.47
SecondaryChange From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery-0.39 ± 0.42-7.60 ± 0.41

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to end of study regardless of seriousness or relationship to investigational product. Time frame for reporting of TEAE was up to 36 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/132 (0%)19/132 (14.4%)61/132 (46.2%)
Dupilumab 300 mg0/143 (0%)6/143 (4.2%)55/143 (38.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboDupilumab 300 mg
Nasal PolypsRespiratory, thoracic and mediastinal disorders7/1322/143
AsthmaRespiratory, thoracic and mediastinal disorders2/1320/143
Aortic Valve StenosisCardiac disorders1/1320/143
Vitreous HaemorrhageEye disorders1/1320/143
Eosinophilic Granulomatosis With PolyangiitisImmune system disorders1/1321/143
Acute SinusitisInfections and infestations1/1320/143
ErysipelasInfections and infestations1/1320/143
PneumoniaInfections and infestations1/1320/143
Clavicle FractureInjury, poisoning and procedural complications1/1320/143
Foot DeformityMusculoskeletal and connective tissue disorders1/1320/143
Most frequent other events
Most frequent other events
EventPlaceboDupilumab 300 mg
NasopharyngitisInfections and infestations20/13219/143
Nasal PolypsRespiratory, thoracic and mediastinal disorders17/13216/143
Injection Site ErythemaGeneral disorders12/1328/143
HeadacheNervous system disorders11/1327/143
EpistaxisRespiratory, thoracic and mediastinal disorders4/13211/143
BronchitisInfections and infestations8/1320/143
AsthmaRespiratory, thoracic and mediastinal disorders8/1323/143
CoughRespiratory, thoracic and mediastinal disorders7/1324/143

Baseline characteristics

Analysis was performed on randomized participants, which included any participant who was allocated to a randomized treatment regardless of whether any treatment kit was used.

Age, Continuous
Age, Continuous(Years)PlaceboDupilumab 300 mgTotal
Mean50.83 ± 13.2150.17 ± 13.5950.49 ± 13.39
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab 300 mgTotal
Female6355118
Male7088158
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumab 300 mgTotal
Hispanic or Latino156
Not Hispanic or Latino130138268
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDupilumab 300 mgTotal
American Indian or Alaska Native011
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American729
White126138264
More than one race000
Unknown or Not Reported011
Nasal Congestion/Obstruction (NC) Symptom Severity Score
Nasal Congestion/Obstruction (NC) Symptom Severity Score(score on a scale)PlaceboDupilumab 300 mgTotal
Mean2.45 ± 0.552.26 ± 0.572.35 ± 0.57
Nasal Polyp Score (NPS)
Nasal Polyp Score (NPS)(score on a scale)PlaceboDupilumab 300 mgTotal
Mean5.86 ± 1.315.64 ± 1.235.75 ± 1.28
08

Study locations

76 sites
  • Investigational Site Number 8400009
    Long Beach, California 90720, United States
  • Investigational Site Number 8400004
    Orange, California 92868, United States
  • Investigational Site Number 8400014
    San Diego, California 92123, United States
  • Investigational Site Number 8400002
    Stockton, California 95207, United States
  • Investigational Site Number 8400016
    Centennial, Colorado 80112, United States
  • Investigational Site Number 8400013
    Tampa, Florida 33613, United States
  • Investigational Site Number 8400022
    West Des Moines, Iowa 50265, United States
  • Investigational Site Number 8400007
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 8400005
    Rochester, Minnesota 55905, United States
  • Investigational Site Number 8400021
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number 8400008
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 8400019
    Tulsa, Oklahoma 74136, United States
  • Investigational Site Number 8400020
    Medford, Oregon 97504, United States
  • Investigational Site Number 8400018
    Charleston, South Carolina 29425, United States
  • Investigational Site Number 8400003
    Nashville, Tennessee 37232-8695, United States
  • Investigational Site Number 8400001
    Dallas, Texas 75231, United States
  • Investigational Site Number 8400015
    Norfolk, Virginia 23507, United States
  • Investigational Site Number 8400010
    Milwaukee, Wisconsin 53226, United States
  • Investigational Site Number 1000003
    Plovdiv, 4002, Bulgaria
  • Investigational Site Number 1000002
    Sofia, 1527, Bulgaria
  • Investigational Site Number 1000001
    Sofia, 1606, Bulgaria
  • Investigational Site Number 2030001
    Hradec Kralove, 50005, Czechia
  • Investigational Site Number 2030002
    Pardubice, 53203, Czechia
  • Investigational Site Number 2030004
    Praha 2, 12808, Czechia
  • Investigational Site Number 2500005
    La Roche Sur Yon, 85925, France
  • Investigational Site Number 2500007
    Lille, 59000, France
  • Investigational Site Number 2500003
    Lyon, 69317, France
  • Investigational Site Number 2500001
    Montpellier, 34000, France
  • Investigational Site Number 2500006
    Nantes, 44035, France
  • Investigational Site Number 2500002
    Toulouse, 31059, France
  • Investigational Site Number 2500004
    Vandoeuvre-Les-Nancy, 54511, France
  • Investigational Site Number 2760001
    Berlin, 13353, Germany
  • Investigational Site Number 2760003
    München, 81377, Germany
  • Investigational Site Number 2760002
    Münster, 48149, Germany
  • Investigational Site Number 3480006
    Budapest, 1062, Hungary
  • Investigational Site Number 3480007
    Budapest, 1083, Hungary
  • Investigational Site Number 3480004
    Budapest, 1115, Hungary
  • Investigational Site Number 3480003
    Budapest, 1125, Hungary
  • Investigational Site Number 3480005
    Debrecen, 4032, Hungary
  • Investigational Site Number 3480002
    Pécs, 7621, Hungary
  • Investigational Site Number 3480001
    Szeged, 6725, Hungary
  • Investigational Site Number 3800007
    Bologna, 40139, Italy
  • Investigational Site Number 3800002
    Catania, 95123, Italy
  • Investigational Site Number 3800004
    Milano, 20132, Italy
  • Investigational Site Number 3800006
    Milano, 20142, Italy
  • Investigational Site Number 3800001
    Pisa, 56124, Italy
  • Investigational Site Number 3800005
    Rozzano, 20089, Italy
  • Investigational Site Number 3800003
    Varese, 21100, Italy
  • Investigational Site Number 5280001
    Amsterdam, 1105 AZ, Netherlands
  • Investigational Site Number 6160002
    Katowice, 40-611, Poland
  • Investigational Site Number 6160001
    Lodz, 90-153, Poland
  • Investigational Site Number 6160003
    Warszawa, 04-141, Poland
  • Investigational Site Number 6420007
    Brasov, 500283, Romania
  • Investigational Site Number 6420013
    Brasov, 500283, Romania
  • Investigational Site Number 6420003
    Bucuresti, 011172, Romania
  • Investigational Site Number 6420009
    Cluj-Napoca, 400015, Romania
  • Investigational Site Number 6420008
    Craiova, 200642, Romania
  • Investigational Site Number 6420010
    Targu-Mures, 540098, Romania
  • Investigational Site Number 6430004
    Moscow, 119435, Russian Federation
  • Investigational Site Number 6430003
    Moscow, 129090, Russian Federation
  • Investigational Site Number 6430001
    Saint-Petersburg, 195030, Russian Federation
  • Investigational Site Number 6430007
    Saint-Petersburg, 197022, Russian Federation
  • Investigational Site Number 6430002
    St-Petersburg, 190013, Russian Federation
  • Investigational Site Number 6430006
    Yaroslavl, 150003, Russian Federation
  • Investigational Site Number 8040002
    Ivano-Frankivsk, 76000, Ukraine
  • Investigational Site Number 8040004
    Kharkiv, 61166, Ukraine
  • Investigational Site Number 8040005
    Kyiv, 01133, Ukraine
  • Investigational Site Number 8040006
    Kyiv, 03680, Ukraine
  • Investigational Site Number 8040001
    Poltava, 36011, Ukraine
  • Investigational Site Number 8040008
    Ternopil, 46000, Ukraine
  • Investigational Site Number 8260001
    Bradford, BD9 6RJ, United Kingdom
  • Investigational Site Number 8260002
    Dundee, DD1 9SY, United Kingdom
  • Investigational Site Number 8260007
    Great Yarmouth, NR31 6LA, United Kingdom
  • Investigational Site Number 8260006
    London, SE1 7EH, United Kingdom
  • Investigational Site Number 8260004
    Stockport, SK2 7JE, United Kingdom
  • Investigational Site Number 8260005
    Wigan, WN1 2NN, United Kingdom
09

References and documents

Publications

  • Peters AT, Soler ZM, Kern RC, Heffler E, Maspero JF, Crampette L, Fujieda S, Lane AP, Zhang H, Nash S, Khan AH, Siddiqui S, Jacob-Nara JA, Rowe P, Deniz Y. Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials. Clin Exp Allergy. 2022 Sep;52(9):1105-1109. doi: 10.1111/cea.14194. Epub 2022 Jul 12. No abstract available. PubMed 35775319 ↗
  • Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. PubMed 35636689 ↗
  • Bachert C, Peters AT, Heffler E, Han JK, Olze H, Pfaar O, Chuang CC, Rout R, Attre R, Goga L, Jacob-Nara JA, Rowe PJ, Deniz Y, Chen Z, Kamat S, Siddiqui S. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. Clin Exp Allergy. 2022 Feb;52(2):244-249. doi: 10.1111/cea.14051. No abstract available. PubMed 35092110 ↗
  • Lee SE, Hopkins C, Mullol J, Msihid J, Guillemin I, Amin N, Mannent LP, Li Y, Siddiqui S, Chuang CC, Kamat S, Khan AH. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy. 2022 Jul;77(7):2211-2221. doi: 10.1111/all.15222. Epub 2022 Feb 1. PubMed 35034364 ↗
  • Bachert C, Corren J, Lee SE, Zhang H, Harel S, Cunoosamy D, Khan AH, Jacob-Nara JA, Siddiqui S, Nash S, Rowe PJ, Deniz Y. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials. Int Forum Allergy Rhinol. 2022 Sep;12(9):1191-1195. doi: 10.1002/alr.22964. Epub 2022 Jan 31. No abstract available. PubMed 34970860 ↗
  • Hellings PW, Peters AT, Chaker AM, Heffler E, Zhang H, Praestgaard A, Nash S, Khan AH, Siddiqui S, Jacob-Nara JA, Rowe PJ, Deniz Y. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022 Jul;12(7):958-962. doi: 10.1002/alr.22944. Epub 2022 Jan 23. No abstract available. PubMed 34911163 ↗
  • Han JK, Bachert C, Lee SE, Hopkins C, Heffler E, Hellings PW, Peters AT, Kamat S, Whalley D, Qin S, Nelson L, Siddiqui S, Khan AH, Li Y, Mannent LP, Guillemin I, Chuang CC. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis. Laryngoscope. 2022 Feb;132(2):265-271. doi: 10.1002/lary.29888. Epub 2021 Dec 1. PubMed 34850966 ↗
  • Chuang CC, Guillemin I, Bachert C, Lee SE, Hellings PW, Fokkens WJ, Duverger N, Fan C, Daizadeh N, Amin N, Mannent LP, Khan AH, Kamat S. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. Laryngoscope. 2022 Feb;132(2):259-264. doi: 10.1002/lary.29911. Epub 2021 Nov 24. PubMed 34817082 ↗
  • Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, Maspero JF, Picado C, Daizadeh N, Ortiz B, Li Y, Ruddy M, Laws E, Amin N. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1. PubMed 34459002 ↗
  • Khan AH, Reaney M, Guillemin I, Nelson L, Qin S, Kamat S, Mannent L, Amin N, Whalley D, Hopkins C. Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2022 May;132(5):933-941. doi: 10.1002/lary.29766. Epub 2021 Aug 26. PubMed 34437720 ↗
  • Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3. PubMed 33710614 ↗
  • Hopkins C, Wagenmann M, Bachert C, Desrosiers M, Han JK, Hellings PW, Lee SE, Msihid J, Radwan A, Rowe P, Amin N, Deniz Y, Ortiz B, Mannent LP, Rout R. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021 Jul;11(7):1087-1101. doi: 10.1002/alr.22780. Epub 2021 Feb 21. PubMed 33611847 ↗
  • Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C, Xu Y, Chuang CC, Neupane B, Msihid J, Mannent LP, Guyot P, Kamat S. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2021 Jun;9(6):2461-2471.e5. doi: 10.1016/j.jaip.2021.01.031. Epub 2021 Feb 4. PubMed 33548517 ↗
  • Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021 May;126(5):584-592.e1. doi: 10.1016/j.anai.2021.01.012. Epub 2021 Jan 16. PubMed 33465455 ↗
  • Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Erratum In: Lancet. 2019 Nov 2;394(10209):1618. doi: 10.1016/S0140-6736(19)32218-4. PubMed 31543428 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Not yet available

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jul 2018, 19 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 19 months is below that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 23, 2016
StartActual
Dec 5, 2016
Primary completionActual
Jul 5, 2018
CompletionActual
Jul 5, 2018
Results first posted
Jul 25, 2019
Last update
Jul 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02912468
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Dec 5, 2016
Primary completion
Jul 5, 2018
Completion
Jul 5, 2018
Results posted
Jul 25, 2019
Last update
Jul 25, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion